Nifty200 Alpha30 News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Glenmark Pharmaceuticals Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Glenmark Pharmaceuticals Ltd.
Rating: 1
Author: ICICI Securities Limited

Keep track of all breaking news and updates on Nifty200 Alpha30 from all sources in a single place.

Load latest

Info Edge (India) Ltd.

18 Jul 2025

1399.80

2.56%

Company Update

Info Edge (India) Ltd - 532777 - Announcement under Regulation 30 (LODR)-Diversification / Disinvestment

BSE India

Intimation pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

pdf

Indian Hotels Company Ltd.

18 Jul 2025

771.70

0.72%

Indian Hotels share rises 2% on strong Q1; should you buy, sell or hold?

Business Standard

Indian Hotels share rose after the company delivered a robust performance in Q1FY26, reporting a 32% Y-o-Y jump in consolidated revenue to 2,102 crore, compared to 1,596 crore in Q1FY25.

Indian Hotels Compan.. has an average target of 890.43 from 7 brokers.

Indian Hotels Q1 Review: Analysts Split As Jefferies Maintains 'Buy', Macquarie Cautious

NDTV Profit | 18 Jul 2025 1 more

Glenmark Pharmaceuticals Ltd.

18 Jul 2025

2184.80

-1.83%

ISB 2001 deal well-done; valuation defies uncertainties ahead

Sell: Glenmark Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Glenmark Pharmaceuticals’ (Glenmark) subsidiary Ichnos Glenmark Innovation (IGI) has out-licensed its oncology asset ISB 2001 to Abbvie in a deal valued at USD 1.925bn, including USD 700mn upfront, USD 1.225bn in milestones and tiered doubledigit royalty on net sales.

Glenmark Pharmaceuticals Ltd. has gained 33.49% in the last 1 Month

Indian Hotels Company Ltd.

18 Jul 2025

771.70

0.72%

Resilience amid turbulence, demand outlook remains robust

Buy: Indian Hotels Company Ltd.

Target

ICICI Securities Limited

Indian Hotels (IH IN) reported Q1FY26 consolidated revenue of INR 20.4bn and EBITDA of INR 5.8bn (2% above I-sec estimate of INR5.7bn) driven by higher standalone ARR of INR 14,552 (up 12% YoY).

Indian Hotels Company Ltd. is trading above all available SMAs

Indian Hotels Company Ltd.

18 Jul 2025

771.70

0.72%

Indian Hotels Company: Q1FY26 Result Review

Buy: Indian Hotels Company Ltd.

Recommendation Target

IDBI Capital

IHCL reported stellar Q1FY26 results beating our and consensus estimates on all key parameters. The company delivered 13th best ever quarter aided by healthy demand in domestic market and improved operational performance of overseas hotels. Moreover, despite unpresented disruptions, RevPAR growth in domestic market is commendable. The management reiterated healthy double digit RevPAR growth in FY26E, aided by healthy demand, increasing FTA and higher spending on MICE, weddings etc. IHCL's new business are growing at a robust pace and will continue to support consolidated earnings. Net sales increased by...

Indian Hotels Company Ltd. is trading above all available SMAs

Indian Hotels Company Ltd.

18 Jul 2025

771.70

0.72%

Result Update:Indian Hotels Co

Buy: Indian Hotels Company Ltd.

Target

Axis Direct

We maintain our BUY rating with TP of Rs 835/share, implying upside of 11% from CMP

ICICI Securities Limited increased Buy price target of Indian Hotels Company Ltd. to 941.0 on 18 Jul, 2025.

HDFC Life Insurance Company Ltd.

18 Jul 2025

752.30

1.73%

Q1FY26 HDFC Life Insurance Co. Ltd.

Buy: HDFC Life Insurance Compan...

Deven Choksey

We reiterate our “BUY” rating on the stock, as we expect strong premium growth,
stable margins, and a resilient product mix to underpin sustainable profitability and market share gains in FY26E.